Cytosorbents (CTSO) Property, Plant & Equipment (Net) Growth (3y) (2013 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PP&E (Net) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | 10.07% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 8.57% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 9.71% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 17.92% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | 3.47% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | - |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 13.19% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | 9.97% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 9.80% |
| 10 | Cytosorbents | 28.81 Mn | 24.01 Mn | 6.13 Mn | -11.12% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -11.12% |
| Dec 31, 2025 | -10.03% |
| Sep 30, 2025 | -8.55% |
| Jun 30, 2025 | -6.08% |
| Mar 31, 2025 | 3.58% |
| Dec 31, 2024 | 20.45% |
| Sep 30, 2024 | 34.63% |
| Jun 30, 2024 | 45.52% |
| Mar 31, 2024 | 59.45% |
| Dec 31, 2023 | 68.02% |
| Sep 30, 2023 | 70.42% |
| Jun 30, 2023 | 75.21% |
| Mar 31, 2023 | 75.05% |
| Dec 31, 2022 | 77.37% |
| Sep 30, 2022 | 77.44% |
| Jun 30, 2022 | 74.49% |
| Mar 31, 2022 | 60.55% |
| Dec 31, 2021 | 43.87% |
| Sep 30, 2021 | 31.33% |
| Jun 30, 2021 | 20.01% |
| Mar 31, 2021 | 14.36% |
| Dec 31, 2020 | 14.76% |
| Sep 30, 2020 | 26.23% |
| Jun 30, 2020 | 39.12% |
| Mar 31, 2020 | 50.20% |
| Dec 31, 2019 | 50.09% |
| Sep 30, 2019 | 45.37% |
| Jun 30, 2019 | 47.47% |
| Mar 31, 2019 | 49.36% |
| Dec 31, 2018 | 45.87% |
| Dec 31, 2017 | 78.70% |
| Sep 30, 2017 | 75.48% |
| Jun 30, 2017 | 61.55% |
| Mar 31, 2017 | 55.86% |
| Dec 31, 2016 | 57.99% |
| Sep 30, 2016 | 63.23% |
| Jun 30, 2016 | 61.39% |
| Mar 31, 2016 | 59.70% |
| Dec 31, 2015 | 56.43% |
| Dec 31, 2014 | 16.60% |
| Sep 30, 2014 | 9.75% |
| Jun 30, 2014 | 7.33% |
| Dec 31, 2013 | 0.06% |